Prime Medicine: adding versatility to gene editing

CRISPR-Cas9 gene editing has only started to scratch the surface of its clinical potential, but next-generation iterations including prime editing from new company Prime aren’t far behind.

Prime Medicine Inc. launched on Tuesday with $315 million in funding and a CRISPR-based technology that adds flexibility and potential safety benefits over other gene editing tools...